Pituitary pars intermedia dysfunction

Last updated

Pituitary pars intermedia dysfunction (PPID), or equine Cushing's disease, is an endocrine disease affecting the pituitary gland of horses. It is most commonly seen in older animals, [1] and is classically associated with the formation of a long, wavy coat (hirsutism) and chronic laminitis.

Contents

Cushing's disease commonly causes hirsutism, muscle wasting along the top line, and abnormal fat distribution. Vieux Cheval-Ile de Batz.JPG
Cushing's disease commonly causes hirsutism, muscle wasting along the top line, and abnormal fat distribution.

Pathophysiology

Unlike the human and canine forms of Cushing's disease, which most commonly affect the pars distalis region of the pituitary gland, equine Cushing's disease is a result of hyperplasia or adenoma formation in the pars intermedia. [2] This adenoma then secretes excessive amounts of normal products, leading to clinical signs.

Dopaminergic control of the pars intermedia

The pituitary gland consists of three parts: the pars nervosa, the pars intermedia, and the pars distalis. The most critical structure to PPID, the pars intermedia, is regulated by the hypothalamus. The neurons of the hypothalamus innervate cells known as melanotropes within the pars intermedia, releasing dopamine which then binds to dopamine receptors on the melanotropes. The activation of these dopamine receptors leads to the inhibition of proopiomelanocortin (POMC) production in these cells. [1]

In PPID-affected horses, dopamine is not produced from these neurons, leading to dopamine levels about 10% of the level normally found in the pars intermedia. [2] This is thought to be due to neurodegeneration of the neurons, secondary to free radical formation and oxidative stress. [3] Without regulation from dopamine, the pars intermedia develops hyperplasia and adenoma formation, leading to gross enlargement and excessive production of POMC. These adenomas also have the potential to compress the hypothalamus and optic chiasm. [1] [2]

POMC

POMC produced from the melanotropes of the pars intermedia is cleaved into adrenocorticotropic hormone (ACTH) and β-lipotropin (β-LPH). The majority of ACTH [1] is then cleaved into α-MSH and corticotropin-like intermediate peptide (CLIP). CLIP is thought to have an influence on subsequent insulin resistance that can be seen in PPID horses. [4]

ACTH is also produced by corticotropes in the pars distalis of the equine pituitary. In a normal horse, this accounts for the majority of ACTH production. ACTH produced by the pars distalis is subject to negative feedback in a normal horse, so high cortisol levels reduce ACTH production by the pituitary, subsequently reducing cortisol levels. In a horse with PPID, ACTH levels are high as a result of pars intermedia production, but it is not subject to negative feedback regulation. Despite the high levels of ACTH, cortisol levels vary, and are sometimes lower than normal. Additionally, hyperplasia of the adrenal cortex is infrequent. [1] The role of ACTH is, therefore, still poorly understood.

Age and breed prevalence

PPID has been diagnosed in horses as young as 7 years old, [1] although most horses are first diagnosed at ages 19 to 20. [1] An estimated 21% of horses older than 15 years have PPID. [5] All breeds may develop PPID, but pony breeds and Morgans seem to be more commonly affected. [1] [6] [7]

Clinical signs

Many signs are associated with PPID, but only a subset of these is displayed in any single horse. Some horses may present with chronic laminitis without other overt signs of the disease. [1]

Laboratory findings

Complete blood counts and serum chemistry profiles may be normal in affected horses. [9] Persistent hyperglycemia and glucosuria are very commonly seen. [1] Hyperlipidemia may be present, especially in ponies. [1] Other abnormalities associated with the disease include mild anemia, neurophilia, lymphopenia, eosinopenia, and increased liver enzymes. [2]

Differentiating from equine metabolic syndrome

PPID shares similarities to equine metabolic syndrome (EMS), which also causes regional adiposity, laminitis, and insulin resistance. Treatment and management may differ between the two endocrinopathies, making differentiation important. Importantly, though, horses with EMS may develop PPID, so both diseases may occur simultaneously. [12]

EMS vs PPID
EMSPPID
Age of Onset5-15 years15+ years
Clinical signsResistance to weight lossHirsutism, increased drinking and urination, muscle atrophy
Serum ACTH levelsNormalElevated

Diagnosis

Plasma ACTH concentration

This test may also be referred to as a ‘’resting ACTH’’, ’’endogenous ACTH’’, or ‘’basal ACTH’’. The majority of ACTH produced in normal horses comes from corticotrope cells in the pars distalis, with only 2% thought to come from melanotropes in the pars intermedia. In horses with PPID, melanotropes produce abnormally high concentrations of ACTH. [8] Basal plasma ACTH concentrations, which measure the blood levels of circulating ACTH, can therefore be useful in diagnosing the disease. [13]

ACTH levels naturally fluctuate in healthy horses, with a significant rise occurring the in autumn (August through October) in North American horses. Horses with PPID have a similar, but much more significant, rise in the autumn. Therefore, a seasonally adjusted reference range must be used that correlates with the time of year the sample is taken. [8] Failure to use a seasonally adjusted reference range may lead to false-positive results in normal horses if they are sampled in the fall. [13] Autumnal testing was thought to be more sensitive and specific than testing at other times of the year; however, this concept has been recently challenged. [5] [13] Basal plasma ACTH levels may increase if the horse is severely ill or under great stress or pain, such as if it has laminitis. However, such events must be fairly significant to confound the results. [8] Additionally, ACTH levels may not be significantly increased early on in the disease, leading to false negatives. [14]

Thyrotropin-releasing hormone stimulation test

Thyrotropin-releasing hormone (TRH) receptors are present in both the melanotropes of the pars intermedia and the corticotropes in the pars distalis. The administration of exogenous TRH causes an increase in ACTH and α-MSH in plasma of both normal horses and those with PPID. In both cases, plasma ACTH peaks 2–10 minutes after administration, before slowly dropping to normal levels over the course of an hour. PPID horses, however, show a much greater peak than normal horses, especially in the autumn. [8] The test is relatively simple, involving one blood sample taken before TRH administration, and one 10 minutes or 30 minutes following TRH. [14] [13]

TRH is currently not licensed for use in horses, and can cause various side effects, including yawning, flehmen, muscle trembling, and coughing. [15] This test is thought to have greater sensitivity than other tests, but has drawbacks including cost, TRH availability, limited repeatability and lack of defined seasonal reference intervals. [8] [13] [16] Due to a lack of seasonal references, it is only recommended for use from December until June. [14]

Dexamethasone suppression test

The dexamethasone suppression test involves administering dexamethasone, a synthetic glucocorticoid, to the horse, and measuring its serum cortisol levels before and 19–24 hours after injection. In a normal horse, dexamethasone administration results in negative feedback to the pituitary, resulting in decreased ACTH production from the pars distalis and, therefore, decreased synthesis of cortisol at the level of the adrenal gland. A horse with PPID, which has an overactive pars intermedia not regulated by glucocorticoid levels, does not suppress ACTH production and, therefore, cortisol levels remain high. False negatives can occur in early disease. [1] Additionally, dexamethasone administration may increase the risk of laminitis in horses already prone to the disease. [8] For these reasons, the dexamethasone suppression test is currently not recommended for PPID testing.

Urinary corticoid-to-creatinine ratio

Although corticoid-to-creatinine ratios are generally higher in horses with PPID, numerous false positives and false negatives occur with this test, so it is not recommended. [1]

Plasma cortisol concentration

Resting plasma cortisol may be slightly elevated in affected horses, but is commonly within normal limits or below normal. Additionally, elevations may occur secondary to stress, concurrent disease, and due to individual variation. Therefore, resting cortisol levels alone are not adequate to diagnose or rule out the presence of PPID. [2]

Current recommendations for testing

As of 2013, horses suspected of having PPID should undergo testing both for the disease and for insulin dysfunction (see below). Horses showing obvious signs of PPID will likely have a positive endogenous ACTH test. Horses with early disease may produce a false-negative result. In these horses, the thyrotropin-releasing hormone stimulation test should either be used as an initial screening test, or to confirm a false resting ACTH. [14]

Insulin dysregulation

Insulin dysregulation is commonly seen in horses with PPID or equine metabolic syndrome. It is of interest primarily because of its link to laminitis. Horses with ID will have an increased insulin response after they are given oral sugars, which will cause a subsequent rise in blood insulin levels, or hyperinsulinemia. Hyperinsulinemia results in decreased tissue sensitivity to insulin, or insulin resistance especially by the skeletal muscle, liver and adipose tissue. Tissue insulin resistance causes increased insulin secretion, which perpetuates the cycle. [4]

The trigger to insulin resistance is not fully understood. Genetics is likely to have some impact on the risk of postprandial hyperinsulinemia. Obesity, pregnancy, PPID, and inflammatory states may contribute to tissue insulin resistance. PPID is thought to result in increased insulin secretion due to higher levels of CLIP produced by melanotrophs, and to cause insulin resistance secondary to hyperadrenocorticism. [4]

Testing for insulin dysregulation

Due to the strong link between PPID and insulin resistance, testing is recommended for all horses suspected or confirmed to be suffering from PPID. There are two tests commonly used for insulin resistance: the oral sugar test and fasting insulin blood concentration. [17]

The fasting insulin concentration involves giving a horse a single flake of hay at 10 pm the night before testing, with blood being drawn the following morning. Both insulin and glucose blood levels are measured. Hyperinsulinemia suggests insulin resistance, but normal or low fasting insulin does not rule out PPID. This test is easy to perform, but is less sensitive than the oral sugar test. [14] It is best used in cases where risks of laminitis make the oral sugar test potentially unsafe. [18]

The oral sugar test also requires giving the horse only a single flake of hay at 10pm the night before the test. The following morning, karo corn syrup is given orally, and glucose and insulin levels are measured at 60 and 90 minutes after administration. Normal or excessively high insulin levels are diagnostic. However, equivocal test results require retesting at a later date, or performing a different test. [14] A similar test is available outside the US, in areas where corn-syrup products are less readily available, where horses are given a morning meal of chaff with dextrose powder, and blood insulin levels are measured 2 hours later. [18]

Management of insulin resistance

The main methods of management involve exercise and diet change, in addition to treatment of PPID. The primary goal is reduction of weight in an obese animal. Diet changes include limiting pasture access and reducing or eliminating grain. Obese animals are often best maintained on a diet consisting of ration balancer and hay, fed at 1.5% body weight and decreased if needed. [18] Feed should be selected based on low nonstructural carbohydrate (NSC) levels. Hay NSC levels may be reduced by soaking it in cold water for 30 minutes. [18]

Exercise is increased in nonlaminitic horses. Animals resistant to weight loss, despite diet and exercise changes, can be placed on levothyroxine to increase metabolism. Metformin can also be used to reduce glucose absorption through the intestinal tract. [18]

Treatment

The primary treatment of PPID is pergolide, a dopamine agonist that provides suppression to the pars intermedia in place of the dysfunctional hypothalamus. Horses should be reassessed in 30 days following the start of treatment, through evaluation of clinical signs and by baseline diagnostic testing, to ensure the appropriate dose is being prescribed. Results from that test dictate changes in dose. Horses that are responding to treatment should be retested every 6 months, including a test in the autumn when a seasonal increase in ACTH occurs, to ensure their ACTH levels are appropriately suppressed during this time. Drug side effects include a transient decrease in appetite, which can be reduced by slowly increasing the dose to therapeutic levels, and by breaking up the daily dose into twice-daily administrations. [14]

Attitude, activity levels, hyperglycemia, and increased drinking and urination are usually improved within 30 days of initiating treatment. Other clinical signs, such as hirsutism, potbellied appearance, muscle wasting, laminitic episodes, and increased predisposition to infection, usually take between 30 days and a year to improve. [14]

Cyproheptadine may be added to the treatment regimen in horses that are inadequately responding to pergolide, [14] but is usually only used in horses with advanced PPID on high doses of pergolide. [18]

See also

Related Research Articles

<span class="mw-page-title-main">Endocrine system</span> Hormone-producing glands of a body

The endocrine system is a messenger system in an organism comprising feedback loops of hormones that are released by internal glands directly into the circulatory system and that target and regulate distant organs. In vertebrates, the hypothalamus is the neural control center for all endocrine systems.

<span class="mw-page-title-main">Cushing's syndrome</span> Symptoms from excessive exposure to glucocorticoids such as cortisol

Cushing's syndrome is a collection of signs and symptoms due to prolonged exposure to glucocorticoids such as cortisol. Signs and symptoms may include high blood pressure, abdominal obesity but with thin arms and legs, reddish stretch marks, a round red face due to facial plethora, a fat lump between the shoulders, weak muscles, weak bones, acne, and fragile skin that heals poorly. Women may have more hair and irregular menstruation. Occasionally there may be changes in mood, headaches, and a chronic feeling of tiredness.

<span class="mw-page-title-main">Anterior pituitary</span> Anterior lobe of the pituitary gland

A major organ of the endocrine system, the anterior pituitary is the glandular, anterior lobe that together with the posterior lobe makes up the pituitary gland (hypophysis) which, in humans, is located at the base of the brain, protruding off the bottom of the hypothalamus.

<span class="mw-page-title-main">Cortisol</span> Human natural glucocorticoid hormone

Cortisol is a steroid hormone, in the glucocorticoid class of hormones and a stress hormone. When used as a medication, it is known as hydrocortisone.

Cushing's disease is one cause of Cushing's syndrome characterised by increased secretion of adrenocorticotropic hormone (ACTH) from the anterior pituitary. This is most often as a result of a pituitary adenoma or due to excess production of hypothalamus CRH that stimulates the synthesis of cortisol by the adrenal glands. Pituitary adenomas are responsible for 80% of endogenous Cushing's syndrome, when excluding Cushing's syndrome from exogenously administered corticosteroids. The equine version of this disease is Pituitary pars intermedia dysfunction.

<span class="mw-page-title-main">Adrenal insufficiency</span> Medical condition

Adrenal insufficiency is a condition in which the adrenal glands do not produce adequate amounts of steroid hormones. The adrenal glands—also referred to as the adrenal cortex—normally secrete glucocorticoids, mineralocorticoids, and androgens. These hormones are important in regulating blood pressure, electrolytes, and metabolism as a whole. Deficiency of these hormones leads to symptoms ranging from abdominal pain, vomiting, muscle weakness and fatigue, low blood pressure, depression, mood and personality changes to organ failure and shock. Adrenal crisis may occur if a person having adrenal insufficiency experiences stresses, such as an accident, injury, surgery, or severe infection; this is a life-threatening medical condition resulting from severe deficiency of cortisol in the body. Death may quickly follow.

<span class="mw-page-title-main">Pergolide</span> Dopamine agonist medication

Pergolide, sold under the brand name Permax and Prascend (veterinary) among others, is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with reduced dopamine activity in the substantia nigra of the brain. Pergolide acts on many of the same receptors as dopamine to increase receptor activity.

<span class="mw-page-title-main">Hypopituitarism</span> Medical condition

Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced by the pituitary gland at the base of the brain. If there is decreased secretion of one specific pituitary hormone, the condition is known as selective hypopituitarism. If there is decreased secretion of most or all pituitary hormones, the term panhypopituitarism is used.

<span class="mw-page-title-main">Metyrapone</span> Chemical compound

Metyrapone, sold under the brand name Metopirone, is a medication which is used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome (hypercortisolism). It is part of the steroidogenesis inhibitor class of drugs.

<span class="mw-page-title-main">Endocrine gland</span> Glands of the endocrine system that secrete hormones to blood

Endocrine glands are ductless glands of the endocrine system that secrete their products, hormones, directly into the blood. The major glands of the endocrine system include the pineal gland, pituitary gland, pancreas, ovaries, testicles, thyroid gland, parathyroid gland, hypothalamus and adrenal glands. The hypothalamus and pituitary glands are neuroendocrine organs.

<span class="mw-page-title-main">Laminitis</span> Disease of the feet of hooved animals

Laminitis is a disease that affects the feet of ungulates and is found mostly in horses and cattle. Clinical signs include foot tenderness progressing to inability to walk, increased digital pulses, and increased temperature in the hooves. Severe cases with outwardly visible clinical signs are known by the colloquial term founder, and progression of the disease will lead to perforation of the coffin bone through the sole of the hoof or being unable to stand up, requiring euthanasia.

<span class="mw-page-title-main">Adrenocorticotropic hormone deficiency</span> Medical condition

Adrenocorticotropic hormone deficiency is a rare disorder characterized by secondary adrenal insufficiency with minimal or no cortisol production and normal pituitary hormone secretion apart from ACTH. ACTH deficiency may be congenital or acquired, and its symptoms are clinically similar to those of glucocorticoid deficiency. Symptoms consist of weight loss, diminished appetite, muscle weakness, nausea, vomiting, and hypotension. Low blood sugar and hyponatremia are possible; however, blood potassium levels typically remain normal because affected patients are deficient in glucocorticoids rather than mineralocorticoids because of their intact renin-angiotensin-aldosterone system. ACTH may be undetectable in blood tests, and cortisol is abnormally low. Glucocorticoid replacement therapy is required. With the exception of stressful situations, some patients with mild or nearly asymptomatic disease may not require glucocorticoid replacement therapy. As of 2008 about two hundred cases have been described in the literature.

Pseudo-Cushing's syndrome or non-neoplastic hypercortisolism is a medical condition in which patients display the signs, symptoms, and abnormal cortisol levels seen in Cushing's syndrome. However, pseudo-Cushing's syndrome is not caused by a problem with the hypothalamic-pituitary-adrenal axis as Cushing's is; it is mainly an idiopathic condition, however a cushingoid appearance is sometimes linked to excessive alcohol consumption. Elevated levels of total cortisol can also be due to estrogen found in oral contraceptive pills that contain a mixture of estrogen and progesterone. Estrogen can cause an increase of cortisol-binding globulin and thereby cause the total cortisol level to be elevated.

An insulin tolerance test (ITT) is a medical diagnostic procedure during which insulin is injected into a patient's vein, after which blood glucose is measured at regular intervals. This procedure is performed to assess pituitary function, adrenal function, insulin sensitivity, and sometimes for other purposes. An ITT is usually ordered and interpreted by an endocrinologist.

A combined rapid anterior pituitary evaluation panel or triple bolus test or a dynamic pituitary function test is a medical diagnostic procedure used to assess a patient's pituitary function. A triple bolus test is usually ordered and interpreted by endocrinologists.

<span class="mw-page-title-main">Equine metabolic syndrome</span> Endocrinopathy affecting horses and ponies

Equine metabolic syndrome (EMS) is an endocrinopathy affecting horses and ponies. It is of primary concern due to its link to obesity, insulin dysregulation, and subsequent laminitis. There are some similarities in clinical signs between EMS and pituitary pars intermedia dysfunction, also known as PPID or Cushing's disease, and some equines may develop both, but they are not the same condition, having different causes and different treatment.

The ACTH test is a medical test usually requested and interpreted by endocrinologists to assess the functioning of the adrenal glands' stress response by measuring the adrenal response to adrenocorticotropic hormone or another corticotropic agent such as tetracosactide or alsactide (Synchrodyn). ACTH is a hormone produced in the anterior pituitary gland that stimulates the adrenal glands to release cortisol, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), and aldosterone.

Corticorelin is a diagnostic agent. It is a synthetic form of human corticotropin-releasing hormone (hCRH).

Hypoadrenocorticism in dogs, or, as it is known in people, Addison's disease, is an endocrine system disorder that occurs when the adrenal glands fail to produce enough hormones for normal function. The adrenal glands secrete glucocorticoids such as cortisol and mineralocorticoids such as aldosterone; when proper amounts of these are not produced, the metabolic and electrolyte balance is upset. Mineralocorticoids control the amount of potassium, sodium, and water in the body. Hypoadrenocorticism is fatal if left untreated.

<span class="mw-page-title-main">Cushing's syndrome (veterinary)</span> Medical condition

Cushing's syndrome disease, also known as hyperadrenocorticism and spontaneous hypercortisolism, is a condition resulting from an endocrine disorder where too much adrenocorticotropic and cortisol hormones are produced, causing toxicity. It may arise in animals as well as in humans. Cushing's is an umbrella term for conditions caused by elevated cortisol and adrenocorticotropic hormone levels.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Reed SM, Bayly WM, Sellon DC (2010). Equine Internal Medicine (3rd ed.). St. Louis, MO: Saunders/Elsevier. ISBN   978-1416056706.
  2. 1 2 3 4 5 6 7 8 9 Robinson E (2003). Current Therapy in Equine Medicine (5th ed.). Elsevier. pp. 807–811. ISBN   978-0-7216-9540-2.
  3. ↑ McFarlane D, Dybdal N, Donaldson MT, Miller L, Cribb AE (February 2005). "Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction". Journal of Neuroendocrinology. 17 (2): 73–80. doi:10.1111/j.1365-2826.2005.01277.x. PMID   15796757. S2CID   39443723.
  4. 1 2 3 Frank N, Tadros EM (January 2014). "Insulin dysregulation". Equine Veterinary Journal. 46 (1): 103–112. doi: 10.1111/evj.12169 . PMID   24033478.
  5. 1 2 3 4 McGowan TW, Pinchbeck GP, McGowan CM (January 2013). "Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses". Equine Veterinary Journal. 45 (1): 66–73. doi: 10.1111/j.2042-3306.2012.00575.x . PMID   22563728.
  6. 1 2 3 4 5 6 7 McGowan TW, Pinchbeck GP, McGowan CM (January 2013). "Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses". Equine Veterinary Journal. 45 (1): 74–9. doi:10.1111/j.2042-3306.2012.00578.x. PMID   22594955.
  7. ↑ Miller MA, Moore GE, Bertin FR, Kritchevsky JE (March 2016). "What's New in Old Horses? Postmortem Diagnoses in Mature and Aged Equids". Veterinary Pathology. 53 (2): 390–398. doi: 10.1177/0300985815608674 . PMID   26459516. S2CID   1596503.
  8. 1 2 3 4 5 6 7 Durham AE, McGowan CM, Fey K, Tamzali Y, Van der Kolk JH (April 2014). "Pituitary pars intermedia dysfunction: diagnosis and treatment". Equine Veterinary Education. 26 (4): 216–223. doi:10.1111/eve.12160.
  9. 1 2 3 4 Horn R, Bamford NJ, Afonso T, Sutherland M, Buckerfield J, Tan RH, et al. (July 2019). "Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction". Equine Veterinary Journal. 51 (4): 440–445. doi:10.1111/evj.13041. hdl: 11343/284846 . PMID   30417404. S2CID   53282993.
  10. 1 2 McFarlane D (April 2011). "Equine pituitary pars intermedia dysfunction". The Veterinary Clinics of North America. Equine Practice. 27 (1): 93–113. doi:10.1016/j.cveq.2010.12.007. PMID   21392656.
  11. ↑ Hofberger S, Gauff F, Licka T (March 2015). "Suspensory ligament degeneration associated with pituitary pars intermedia dysfunction in horses". Veterinary Journal. 203 (3): 348–350. doi:10.1016/j.tvjl.2014.12.037. PMID   25641552.
  12. ↑ Frank N, Geor RJ, Bailey SR, Durham AE, Johnson PJ (May 2010). "Equine metabolic syndrome". Journal of Veterinary Internal Medicine. 24 (3): 467–475. doi: 10.1111/j.1939-1676.2010.0503.x . PMID   20384947.
  13. 1 2 3 4 5 Horn R, Stewart AJ, Jackson KV, Dryburgh EL, Medina-Torres CE, Bertin FR (January 2021). "Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses". Journal of Veterinary Internal Medicine. 35 (1): 560–570. doi:10.1111/jvim.16017. PMC   7848300 . PMID   33368633.
  14. 1 2 3 4 5 6 7 8 9 Frank N, Andrews F, Durham A, Kritchevsky J, McFarlane D, Schott H, et al. (PPID Working Group) (2015). Recommendations for the diagnosis and treatment of pituitary pars intermedia dysfunction (PPID) (PDF). Equine Endocrinology Group. pp. 4–5. Archived from the original (PDF) on 22 May 2020.
  15. ↑ Beech J, Boston R, Lindborg S, Russell GE (August 2007). "Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia". Journal of the American Veterinary Medical Association. 231 (3): 417–26. doi:10.2460/javma.231.3.417. PMID   17669045.
  16. ↑ Kam YN, McKenzie K, Coyle M, Bertin FR (October 2021). "Repeatability of a thyrotropin-releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses". Journal of Veterinary Internal Medicine. 35 (6): 2885–2890. doi:10.1111/jvim.16281. PMC   8692209 . PMID   34642962. S2CID   238747245.
  17. ↑ Bertin FR, de Laat MA (September 2017). "The diagnosis of equine insulin dysregulation" (PDF). Equine Veterinary Journal. 49 (5): 570–576. doi:10.1111/evj.12703. PMID   28543410. S2CID   39553871.
  18. 1 2 3 4 5 6 Frank N, Geor R (January 2014). "Current best practice in clinical management of equine endocrine patients". Equine Veterinary Education. 26 (1): 6–9. doi:10.1111/eve.12130.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.